Literature DB >> 27330454

AES Position Statement on Generic Substitution of Antiepileptic Drugs.

David G Vossler1, Gail D Anderson2, Jacquelyn Bainbridge3.   

Abstract

Year:  2016        PMID： 27330454      PMCID： PMC4913860          DOI： 10.5698/1535-7511-16.3.209

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  8 in total

Review 1.  Generic substitutions for antiepileptic drugs.

Authors:  M R Nuwer; T R Browne; W E Dodson; F E Dreifuss; J Engel; I E Leppik; R H Mattson; J Penry; D M Treiman; B J Wilder
Journal:  Neurology       Date:  1990-11       Impact factor: 9.910

2.  Assessing bioequivalence of generic antiepilepsy drugs.

Authors:  Gregory L Krauss; Brian Caffo; Yi-Ting Chang; Craig W Hendrix; Kelly Chuang
Journal:  Ann Neurol       Date:  2011-06-29       Impact factor: 10.422

3.  Bioequivalence of generic drugs: a simple explanation for a US Food and Drug Administration requirement.

Authors:  Chittaranjan Andrade
Journal:  J Clin Psychiatry       Date:  2015-06       Impact factor: 4.384

4.  Placebo effect of medication cost in Parkinson disease: a randomized double-blind study.

Authors:  Alberto J Espay; Matthew M Norris; James C Eliassen; Alok Dwivedi; Matthew S Smith; Christi Banks; Jane B Allendorfer; Anthony E Lang; David E Fleck; Michael J Linke; Jerzy P Szaflarski
Journal:  Neurology       Date:  2015-01-28       Impact factor: 9.910

5.  Variations in pill appearance of antiepileptic drugs and the risk of nonadherence.

Authors:  Aaron S Kesselheim; Alexander S Misono; William H Shrank; Jeremy A Greene; Michael Doherty; Jerry Avorn; Niteesh K Choudhry
Journal:  JAMA Intern Med       Date:  2013-02-11       Impact factor: 21.873

6.  Assessing bioequivalence of generic modified-release antiepileptic drugs.

Authors:  Emily L Johnson; Yi-Ting Chang; Barbara Davit; Barry E Gidal; Gregory L Krauss
Journal:  Neurology       Date:  2016-03-25       Impact factor: 9.910

7.  Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.

Authors:  Michael D Privitera; Timothy E Welty; Barry E Gidal; Francisco J Diaz; Ron Krebill; Jerzy P Szaflarski; Barbara A Dworetzky; John R Pollard; Edmund J Elder; Wenlei Jiang; Xiaohui Jiang; Michel Berg
Journal:  Lancet Neurol       Date:  2016-02-12       Impact factor: 44.182

8.  Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.

Authors:  Tricia Y Ting; Wenlei Jiang; Robert Lionberger; Jessica Wong; Jace W Jones; Maureen A Kane; Allan Krumholz; Robert Temple; James E Polli
Journal:  Epilepsia       Date:  2015-07-23       Impact factor: 5.864
  8 in total
  12 in total

1.  Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs.

Authors:  Joshua J Gagne; Jennifer R Popovic; Michael Nguyen; Sukhminder K Sandhu; Patty Greene; Rima Izem; Wenlei Jiang; Zhong Wang; Yueqin Zhao; Andrew B Petrone; Anita K Wagner; Sarah K Dutcher
Journal:  Drug Saf       Date:  2018-12       Impact factor: 5.606

2.  Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy.

Authors:  Sharmila Das; Dong Guo; Xiaohui Jiang; Wenlei Jiang; Yan Shu; Tricia Y Ting; James E Polli
Journal:  Pharm Res       Date:  2020-02-26       Impact factor: 4.200

Review 3.  Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.

Authors:  Zhichuan Li; Lanyan Fang; Wenlei Jiang; Myong-Jin Kim; Liang Zhao
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-19       Impact factor: 5.081

4.  Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).

Authors:  Md Motiur Rahman; Yasser Alatawi; Ning Cheng; Jingjing Qian; Annya V Plotkina; Peggy L Peissig; Richard L Berg; David Page; Richard A Hansen
Journal:  Epilepsy Res       Date:  2017-06-13       Impact factor: 3.045

5.  Efficacy and safety of switching from brand-name to domestic generic levetiracetam in children with epilepsy.

Authors:  Ming-Juan Liang; Wei-Feng Qiu; Jing-Wen Zhang; Xue-Ping Li; Gang-An Shi; Qiong-Xiang Zhai; Yu-Xin Zhang; Zhi-Hong Chen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-03-15

Review 6.  Therapeutic Basis of Generic Substitution of Antiseizure Medications.

Authors:  Sarah Elmer; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2022-03-03       Impact factor: 4.402

Review 7.  A Clinician's Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy.

Authors:  James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jul-Aug

Review 8.  Epilepsy during pregnancy: focus on management strategies.

Authors:  Laura M Borgelt; Felecia M Hart; Jacquelyn L Bainbridge
Journal:  Int J Womens Health       Date:  2016-09-19

9.  Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.

Authors:  Magdalena Bosak; Agnieszka Słowik; Wojciech Turaj
Journal:  Drug Des Devel Ther       Date:  2017-08-03       Impact factor: 4.162

10.  Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.

Authors:  Muhammad M Hammami; Sophia J S De Padua; Rajaa Hussein; Eman Al Gaai; Nesrine A Khodr; Reem Al-Swayeh; Syed N Alvi; Nada Binhashim
Journal:  BMC Pharmacol Toxicol       Date:  2017-12-08       Impact factor: 2.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.